Figure 4 Tacrolimus could activate MCs via MRGPRX2 in vitro.
(A) Intracellular calcium concentrations of LAD2 cells treated by tacrolimus. (B) Intracellular calcium concentrations of LAD2 cells treated by C48/80. Human LAD2 cells were treated with tacrolimus for 30 minutes, and C48/80 was used to set positive control.(C) β hexosaminidase release rate, and (D) levels of tryptase, MCP-1 and IL-8 of LAD2 cells (mean ± SEM, n = 3). (E)Intracellular calcium concentrations of MrgprB2-HEK293 cells and(F) NC-HEK293 cells treated by tacrolimus. MRGPRX2-knockdown LAD2 cells were also treated by tacrolimus. (G) β hexosaminidase release rate, and (H) levels of tryptase, MCP-1 and IL-8 of NC-LAD2 cells and MRGPRX2-knockdown LAD2 cells (mean ± SEM, n = 3). All experiments were repeated 3 times. Statistical significance was accepted at p < 0.05 (*p < 0.05, **p < 0.01 and ***p<0.005) by two-tailed unpaired Student’s t-test.